Engineered immune cells take aim at stubborn blood cancers
Disease control
Not yet recruiting
This phase 1 trial is testing a new kind of CAR-T cell therapy, called LMY-922, for people with certain blood cancers that have not responded to standard treatments. The therapy uses donor immune cells engineered to target a protein called BAFF on cancer cells. The study aims to …
Phase: PHASE1 • Sponsor: Luminary Therapeutics • Aim: Disease control
Last updated Jul 02, 2026 08:00 UTC